Literature DB >> 12019115

Method for measuring postantifungal effect in Aspergillus species.

Roxana G Vitale1, Johan W Mouton, Javier Afeltra, Jacques F G M Meis, Paul E Verweij.   

Abstract

An in vitro method for determination of postantifungal effect (PAFE) in molds was developed by using three isolates each of Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, and A. ustus. MICs of amphotericin B and itraconazole were determined by using National Committee for Clinical Laboratory Standards guidelines (M38-P). The inoculum was prepared in RPMI 1640 broth buffered with MOPS (morpholinepropanesulfonic acid) at pH 7.0, and conidia were exposed to amphotericin B and itraconazole at concentrations of 4, 1, and 0.25 times the MIC, each for 4, 2, and 1 h at 37 degrees C. The same procedure was followed for controls with drug-free medium. Following exposure, the conidia were washed three times in saline and the numbers of CFU per milliliter were determined. Exposed and control conidia were then inoculated into microtitration plates and incubated at 37 degrees C for 48 h in a spectrophotometer reader. The optical density (OD) was measured automatically at 10-min intervals, resulting in growth curves. PAFE was quantified by comparing three arbitrary points in the control growth curve, the first increase of OD and the points when 20 and 50% of the maximal growth were reached, with the growth curve of drug-exposed conidia. Amphotericin B induced PAFE in A. fumigatus at four times the MIC after 2 and 4 h of exposure ranging from 1.83 to 6.00 h and 9.33 to 10.80 h, respectively. Significantly shorter PAFEs or lack of PAFE was observed for A. terreus, A. ustus, and A. nidulans. Itraconazole did not induce measurable PAFE in the Aspergillus isolates at any concentration or exposure time tested. Further studies are warranted to investigate the implications of PAFE in relation to clinical efficacy and dosing frequency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019115      PMCID: PMC127200          DOI: 10.1128/AAC.46.6.1960-1965.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Pharmacodynamic effects of subinhibitory antibiotic concentrations.

Authors:  I Odenholt
Journal:  Int J Antimicrob Agents       Date:  2001-01       Impact factor: 5.283

2.  Analysis of growth characteristics of filamentous fungi in different nutrient media.

Authors:  J Meletiadis; J F Meis; J W Mouton; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

3.  Influence of pH and concentration on the postantifungal effect and on the effects of sub-MIC concentrations of 4 antifungal agents on previously treated Candida spp.

Authors:  M T García; M T Llorente; F Mínguez; J Prieto
Journal:  Scand J Infect Dis       Date:  2000

4.  Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.

Authors:  M Boogaerts; D J Winston; E J Bow; G Garber; A C Reboli; A P Schwarer; N Novitzky; A Boehme; E Chwetzoff; K De Beule
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

5.  Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.

Authors:  D Andes; T Stamsted; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.

Authors:  E Dannaoui; E Borel; F Persat; M A Piens; S Picot
Journal:  J Med Microbiol       Date:  2000-07       Impact factor: 2.472

7.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 8.  Antifungal pharmacodynamics: review of the literature and clinical applications.

Authors:  E S Dodds; R H Drew; J R Perfect
Journal:  Pharmacotherapy       Date:  2000-11       Impact factor: 4.705

9.  Turbidometric characterization of the postantifungal effect: comparative studies with amphotericin B, 5-fluorocytosine and miconazole on Candida albicans.

Authors:  G M Scalarone; Y Mikami; N Kurita; Y Ichihara; K Yazawa; M Miyaji
Journal:  Mycoses       Date:  1991 Jul-Aug       Impact factor: 4.377

10.  Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate.

Authors:  N Collette; P van der Auwera; A P Lopez; C Heymans; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  6 in total

Review 1.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Expression turnover profiling to monitor the antifungal activities of amphotericin B, voriconazole, and micafungin against Aspergillus fumigatus.

Authors:  Yanan Zhao; Padmaja Paderu; Steven Park; Aleksandra Dukhan; Meredith Senter; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

3.  Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Rafal Al-Saigh; Maria Siopi; Nikolaos Siafakas; Aristea Velegraki; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

4.  Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi.

Authors:  Joseph Meletiadis; Debbie T A te Dorsthorst; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

5.  Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus.

Authors:  Saskia du Pré; Nicola Beckmann; Mariana Cruz Almeida; Graham E M Sibley; Derek Law; Alexandra C Brand; Mike Birch; Nick D Read; Jason D Oliver
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis.

Authors:  Khojasteh Shirkhani; Ian Teo; Darius Armstrong-James; Sunil Shaunak
Journal:  Nanomedicine       Date:  2015-03-16       Impact factor: 5.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.